Kantarjian, Hagop, 1952-
Kantarjian, Hagop M., 1952-....
Kantarjian, Hagop
Kantarjian, Hagop (Hagop M.), 1952-
Hagop Kantarjian hematologist
VIAF ID: 61710982 ( Personal )
Permalink: http://viaf.org/viaf/61710982
Preferred Forms
- 100 0 _ ‡a Hagop Kantarjian ‡c hematologist
- 200 _ | ‡a Kantarjian ‡b Hagop M. ‡f 1952-....
- 100 1 _ ‡a Kantarjian, Hagop
-
-
- 100 1 _ ‡a Kantarjian, Hagop M. ‡d 1952-...
- 100 1 _ ‡a Kantarjian, Hagop M., ‡d 1952-....
-
- 100 1 _ ‡a Kantarjian, Hagop ‡d 1952-
- 100 1 _ ‡a Kantarjian, Hagop ‡d 1952-
-
-
-
- 100 1 _ ‡a Kantarjian, Hagop, ‡d 1952-
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Advances in the treatment of adult acute lymphocytic leukemia | |
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors | |
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia | |
Leukemias Principles and Practice of Therapy | |
The MD Anderson manual of medical oncology | |
Medical management of chronic myelogenous leukemia | |
Medical management of hematological malignant diseases | |
Molecular genetics and therapy of leukemia | |
Multicenter, randomized, Open-Label, Phase III, trial of Decitabine Versus Patient Choice, with physician advide, of either supportive care or Low-Dose Cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | |
New advances in the treatment of hematologic malignancies : focus on topoisomerase I inhibitors | |
Purine nucleoside phosphorylase (PNP): a novel target in leukemias and lymphomas | |
Targeting different pathways to prevent tumor cell development | |
Therapy of hematopoietic neoplasia, c1991: | |
Workshop on the Clinical Results with Decitabine (5-aza-2'-deoxycytidine) in Hematologic Malignancies, Paris, France, 30 May 1996 : peer-reviewed proceedings |